Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.89)
# 292
Out of 4,630 analysts
746
Total ratings
54.2%
Success rate
23.9%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $4.19 | - | 2 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $113 → $110 | $52.71 | +108.71% | 26 | Aug 7, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $146 → $137 | $98.13 | +39.61% | 33 | Aug 6, 2026 | |
| BMEA Biomea Fusion | Maintained: Buy | $9 → $7 | $1.26 | +457.77% | 2 | Aug 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $152 → $160 | $115.39 | +38.67% | 22 | Aug 5, 2026 | |
| ANNX Annexon | Initiated Coverage: Sell | $3 | $5.36 | -43.98% | 1 | Jul 21, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $745 → $739 | $514.49 | +43.64% | 62 | Jul 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $137 → $165 | $147.97 | +11.51% | 37 | Jul 17, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | n/a | $84.22 | - | 49 | Jul 7, 2026 | |
| DBVT DBV Technologies | Maintained: Buy | $55 | $14.33 | +283.81% | 45 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $12 | $9.31 | +28.89% | 21 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $11 | $3.00 | +266.67% | 81 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 → $150 | $45.86 | +227.08% | 28 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $11 | $3.73 | +194.91% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $25 | $3.99 | +527.35% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $74 | $35.18 | +110.38% | 34 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $86 | $65.53 | +31.24% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $28 | $9.62 | +191.21% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.82 | +340.77% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.24 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $30.16 | - | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $11 | $5.77 | +90.64% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $4.16 | +332.69% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $4 | $0.534 | +649.06% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $7.72 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.74 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $26.55 | n/a | 1 | May 12, 2023 |
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $4.19
Upside: -
Structure Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $113 → $110
Current: $52.71
Upside: +108.71%
Mirum Pharmaceuticals
Aug 6, 2026
Maintained: Buy
Price Target: $146 → $137
Current: $98.13
Upside: +39.61%
Biomea Fusion
Aug 6, 2026
Maintained: Buy
Price Target: $9 → $7
Current: $1.26
Upside: +457.77%
Rhythm Pharmaceuticals
Aug 5, 2026
Maintained: Buy
Price Target: $152 → $160
Current: $115.39
Upside: +38.67%
Annexon
Jul 21, 2026
Initiated Coverage: Sell
Price Target: $3
Current: $5.36
Upside: -43.98%
Madrigal Pharmaceuticals
Jul 17, 2026
Maintained: Buy
Price Target: $745 → $739
Current: $514.49
Upside: +43.64%
Protagonist Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: $137 → $165
Current: $147.97
Upside: +11.51%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $84.22
Upside: -
DBV Technologies
Jun 30, 2026
Maintained: Buy
Price Target: $55
Current: $14.33
Upside: +283.81%
May 19, 2026
Maintained: Buy
Price Target: $35 → $12
Current: $9.31
Upside: +28.89%
May 14, 2026
Maintained: Buy
Price Target: $14 → $11
Current: $3.00
Upside: +266.67%
May 14, 2026
Maintained: Buy
Price Target: $170 → $150
Current: $45.86
Upside: +227.08%
May 13, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $3.73
Upside: +194.91%
May 13, 2026
Maintained: Buy
Price Target: $26 → $25
Current: $3.99
Upside: +527.35%
May 13, 2026
Maintained: Buy
Price Target: $52 → $74
Current: $35.18
Upside: +110.38%
May 12, 2026
Maintained: Buy
Price Target: $61 → $86
Current: $65.53
Upside: +31.24%
May 7, 2026
Maintained: Buy
Price Target: $25 → $28
Current: $9.62
Upside: +191.21%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.82
Upside: +340.77%
Feb 17, 2026
Maintained: Buy
Price Target: n/a
Current: $9.24
Upside: -
Jan 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $30.16
Upside: -
Oct 23, 2025
Maintained: Buy
Price Target: $8 → $11
Current: $5.77
Upside: +90.64%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $4.16
Upside: +332.69%
Oct 6, 2025
Maintained: Buy
Price Target: $15 → $4
Current: $0.534
Upside: +649.06%
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $7.72
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $16.74
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $24
Current: $26.55
Upside: n/a